Background: The ability to profile gene expression at the single-cell resolution offers the unprecedent opportunity to define the complex cellular heterogeneity of the brain in response to pathology. However, single-cell transcriptomics, particularly within the context of postmortem human brain samples, only provide a static snapshot of the underlying transcriptional mechanisms driving the initiation and progression of diseases.
Method: To gain a more comprehensive picture of disease-associated transcriptional programs, our research integrates single-cell genomics with cellular reprogramming techniques for data-driven mechanistic studies with human-based cellular models of the brain. Here, I will discuss our recent effort in profiling the single-cell transcriptome and epigenome of microglia isolated from human brains with varying degrees of Alzheimer's disease (AD) pathology.
Result: We generated an extensive data set of over 150,000 unique microglial transcriptomes from over 400 postmortem human brains with and without AD pathology. Integrating our big data approach with targeted CRISPR-mediated perturbations in microglia derived from induced pluripotent stem cells (iPSCs), we defined the temporal kinetics of inflammatory transcriptional programs adopted by microglia in response to AD. Through the lens of single-cell genomics and cellular reprogramming, I will also discuss our current work investigating the pathophysiological role of hyperexcitable circuits in the etiology of neuropsychiatric symptoms of AD.
Conclusion: Our study provides essential insight into the progression of inflammatory states in microglia, providing a roadmap for therapeutics aimed at curbing neuroinflammation and microglia pathology associated with AD in a disease-stage specific manner.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.087780 | DOI Listing |
Alzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Alzheimer's disease (AD) is the leading cause of dementia worldwide. The recent announcement that lecanemab, a monoclonal antibody targeting amyloid-b, can slow down cognitive decline in AD is a great step forward in the battle against the disease. However, the modest success achieved in the clinical trial speak to the need for developing additional pharmaceutical approaches to target other key features of AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Allen Institute for Brain Science, Seattle, WA, USA.
Background: Applying single-cell RNA sequencing (scRNA-seq) to the study of neurodegenerative disease has propelled the field towards a more refined cellular understanding of Alzheimer's disease (AD); however, directly linking protein pathology to transcriptomic changes has not been possible at scale. Recently, a high-throughput method was developed to generate high-quality scRNA-seq data while retaining cytoplasmic proteins. Tau is a cytoplasmic protein and when hyperphosphorylated is integrally involved in AD progression.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Laboratory for Neuropathology, KU Leuven, Leuven, Belgium.
Background: In 43-63% of symptomatic Alzheimer's disease (AD) patients, there is an observed accumulation of misfolded alpha-synuclein (αSyn). Two primary αSyn subtypes have been identified based on the underlying spreading pattern of this pathology: caudo-rostral and amygdala-predominant. Interactions between pathological TDP-43, Tau, and αSyn can aggravate their spread and aggregation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Heterogeneity in the progression of clinical dementia poses a significant challenge, impeding the effectiveness of current therapies for Alzheimer's disease (AD). To decipher the molecular mechanisms governing heterogeneity in AD progression that remains a critical knowledge gap precluding rational therapeutic design, we investigated the biochemical and biophysical properties of tau present in the inferior temporal gyrus (ITG) and prefrontal cortex (PFC) brain regions of AD patients who had varying disease progression rates. To explore gene expression changes in the ITG which are associated with tau pathology and cognitive decline, we used RNA sequencing for molecular characterization of patients displaying tau and clinical heterogeneity.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brunel University London, London, United Kingdom.
Background: Psychosis occurs in 30-40% of individuals with AD. New insights into disease mechanisms may lead to novel pharmacological targets and treatments. Previous studies have focused on bulk tissue analysis with limited results.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!